FOCUS:Focus On Coronary Unstable Syndromes

Inclusion Criteria: * Subject either not of childbearing potential or is not pregnant and agrees to use contraceptive measure for the duration of the study * Subjects presenting within 12 hours after the last episode of chest pain with: * An accelerating pattern of anginal pain * A prolonged or recurrent anginal pain at rest or with minimal effort AND * Evidence of myocardial ischemia on ECG manifested by at least one of the following ECG criteria: - new persistent or transient ST-segment depression OR transient or reversible ST-segment elevation or new persistent or transient T-wave inversion OR Abnormal cardiac markers defined as: CK-MB greater than the upper limit of normal Troponin T or I level greater than the upper limit of normal. Exclusion Criteria: * Known or suspected pregnancy or actively breast-feeding * Female of childbearing potential not using or planning to use a reliable method of contraception * Treatment with Hormone Replacement Therapy at time of randomization * Angina precipitated by obvious provoking factors * Heart Failure defined as known ejection fraction less or equal to 40% or NYHA (New York Heart Association) class III pr IV * Type I Diabetes Mellitus * Type II diabetes requiring insulin therapy * Hyperkaliemia * Acute chronic inflammatory, collagen tissue disease, auto-immune disease or cancer and/or requiring the use of anti-inflammatory or anti-neoplastic agents at the time of randomization * Use of a non-steriodal anti-inflammatory agent, coxibs, or anti-neoplasic agent within last 7 days * Use of any oral or intra-venous steroidal agent in the last 7 days before study entry * Uncontrolled hypertension * Systolic pressure \< 100 mmHg at randomization * Likelihood of requiring treatment during the study period with drugs not permitted by the protocol * Treatment with any investigational product or device in the last 4 weeks * Previous participation into the trial * History of hypersensitivity, allergy, or intolerance to Angiotensin-Converting Enzyme inhibitors. * Severe cardiovascular diseases requiring urgent therapy * Severe or co-morbid condition * History of cancer not known to be disease free, with the exception of basal cell carcinoma of the skin * Clinically important systemic disorder * Impaired hepatic function * Clinically important chronic or acute renal failure * History of drug or alcohol abuse